Search

Displaying results 2151 - 2160 of 2955 in total
  1. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022...

  2. Drug

    Nicotinamide adenine dinucleotide phosphate

    go.drugbank.com/drugs/DB03461
    Experimental

    (Dorland, 27th ed)

  3. Drug

    Prednisolone sodium metazoate

    go.drugbank.com/drugs/DB05340
    Investigational

    ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon. Releasing the drug directly into the colon reduces the potential for significant ...

  4. Drug

    Morniflumate

    go.drugbank.com/drugs/DB09285
    Investigational

    Morniflumate is a non-steroidal anti-inflammatory drug with antipyretic properties. It is the morpholinoethyl ester of niflumic acid . In one study, post morniflumate ingestion, physical examination and clinical symptoms of those with br...

  5. Drug

    Luteinizing hormone

    go.drugbank.com/drugs/DB14741
    ApprovedInvestigational

    Mixtures: MENOGON 75 IU LIYOFILIZE TOZ ICEREN AMPUL,5 ADET, MENOPUR 150 IU IM VE SC ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 5 ADET
  6. Drug

    Insulin icodec

    go.drugbank.com/drugs/DB16693
    ApprovedInvestigational

    [L51078] In July 2024, the US FDA rejected the approval of insulin icodec, citing concerns regarding hypoglycemia and the indication being sought for type 1 diabetes mellitus. … [L51078]The US FDA subsequently approved insulin icodec in March 2026 for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [L56102]

  7. Drug

    Tezacaftor

    go.drugbank.com/drugs/DB11712
    ApprovedInvestigational

    [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018.

  8. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    [L48241,A232573] Pimavanserin was also under review as a potential treatment for dementia-related psychosis; however, as of April 2021, FDA approval has not been granted for this indication despite previous … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized

  9. Drug

    Glutamic acid

    go.drugbank.com/drugs/DB00142
    ApprovedInvestigationalNutraceutical

    A peptide that is a homopolymer of glutamic acid.

    Mixtures: Olimel 7.6% E, Olimel 4.4% E
  10. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.